Pacific Biosciences of California, Inc. (NASDAQ: PACB), provider of Single Molecule Real Time (SMRT ®) sequencing products, announced today that the company has partnered with Cycle Computing to optimize the PacBio RS SMRT Analysis software for the cloud. Preliminary demonstrations of the solution will be presented this week by Cycle Computing at the Bio-IT World Cloud Computing conference on September 20 in La Jolla, California and the Amazon Web Services Genomics Event on September 22 in Seattle, Washington.
The cloud-based version of the SMRT Analysis software suite is designed to provide dynamic, high performance computing that scales to meet the data analysis needs for SMRT sequencing and supports a workflow that includes sample preparation, sequencing and completed data analysis in less than one day. A beta version of the solution is expected to be available with the next major PacBio RS upgrade, currently scheduled for the end of 2011.
“Analysis of long, single molecule, real-time sequencing reads from unamplified samples without the need to maintain complex and expensive hardware and software will offer customers more flexibility to realize the potential of the PacBio RS,” said Edwin Hauw, Director of Software Product Management for Pacific Biosciences. “By leveraging Cycle Computing’s expertise in building scalable, high performance cloud computing applications our goal is to provide the best balance of performance and convenience for customers.”
For more information about PacBio’s SMRT Analysis software, see the PacBio DevNet site at http://www.pacbiodevnet.com. For more information about Pacific Biosciences, please visit www.pacificbiosciences.com. You can also follow the company on Twitter: www.twitter.com/pacbio.About Pacific Biosciences Pacific Biosciences’ mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research. The company has developed a novel approach to studying the synthesis and regulation of DNA, RNA and proteins. Combining recent advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, Pacific Biosciences has created a powerful technology platform called single molecule, real-time, or SMRT ®, technology. SMRT technology enables real-time analysis of biomolecules with single molecule resolution, which has the potential to transform the understanding of biological systems by providing a window into these systems that has not previously been open for scientific study. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements may contain words such as "believe," "may," "estimate," "anticipate," "continue," "intend," "expect," "plan," the negative of these terms, or other similar expressions, and include the assumptions that underlie such statements. Such statements include, but are not limited to, statements regarding the Company’s SMRT technology. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to risks discussed from time to time in documents Pacific Biosciences of California, Inc. has filed with the Securities and Exchange Commission, including the risks identified under the section captioned "Risk Factors" in its recently filed Quarterly Report on Form 10-Q. All forward-looking statements are based on estimates, projections and assumptions as of the date hereof. Pacific Biosciences undertakes no obligation to update any forward-looking statements.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.